» Articles » PMID: 20795574

Sclerochorioretinal Abnormalities in Hypercholesterolemic Rabbits Treated with Rosiglitazone

Overview
Specialty Radiology
Date 2010 Aug 28
PMID 20795574
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: To evaluate early retinal, choroidal, and scleral abnormalities induced by a hypercholesterolemic diet and the prevention of these abnormalities after oral administration of rosiglitazone in rabbits.

Materials And Methods: Fifty-four New Zealand rabbits were divided into four study groups: control group, normal diet; group 1, hypercholesterolemic diet; group 2, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone from day 14 after beginning the diet; and group 3, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone since the beginning of the experiment. Sclera and choroid underwent histologic and histomorphometric analyses. Retina underwent immunohistochemical analysis with anti-calretinin and anti-glial fibrillary acidic protein (GFAP) antibodies.

Results: No abnormalities were observed in the control group. Group 1 had significant increases in scleral and choroidal thicknesses compared with the control group (P < .01) and group 3 (P < .05). Group 1 presented significant increases in immunoreactivity (P < .001) to the anti-calretinin antibody compared with the other groups. Groups 2 and 3 had significant (P < .002) increases in calretinin immunoreactivity compared with the control group. GFAP was negative in all groups.

Conclusion: The hypercholesterolemic diet induced early retinal, choroidal, and scleral abnormalities. Rosiglitazone preserved the structural anatomy.

Citing Articles

Effect of candesartan on the expression of sclera-choroidal intercellular adhesion molecule-1 in hypercholesterolemic models.

Torres R, Luchini A, Torres R, Oliveira L, Torres C, Torres R Clinics (Sao Paulo). 2014; 69(2):145-9.

PMID: 24519206 PMC: 3912332. DOI: 10.6061/clinics/2014(02)11.